These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38923837)

  • 41. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
    Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
    Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report.
    Alabed IB
    Medicine (Baltimore); 2014 Sep; 93(14):e72. PubMed ID: 25255019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane.
    Satoh M; Richards HB; Shaheen VM; Yoshida H; Shaw M; Naim JO; Wooley PH; Reeves WH
    Clin Exp Immunol; 2000 Aug; 121(2):399-405. PubMed ID: 10931159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis.
    Park JA
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes.
    Li M; Bai W; Wang Y; Song L; Zhang S; Zhao J; Wu C; Li M; Tian X; Zeng X
    Clin Rheumatol; 2023 Jun; 42(6):1573-1584. PubMed ID: 36797549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus.
    Kim D; Choi J; Cho SK; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Jun; 46(6):782-787. PubMed ID: 27745903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintenance of autoantibody production in pristane-induced murine lupus.
    Han S; Zhuang H; Xu Y; Lee P; Li Y; Wilson JC; Vidal O; Choi HS; Sun Y; Yang LJ; Reeves WH
    Arthritis Res Ther; 2015 Dec; 17():384. PubMed ID: 26717913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus.
    McClung DM; Kalusche WJ; Jones KE; Ryan MJ; Taylor EB
    Physiol Rep; 2021 Feb; 9(3):e14734. PubMed ID: 33527772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER).
    Garcia-Villanueva MJ; Garrote-Corral S; Pego-Reigosa JM; Jiménez Otero N; Uriarte Isazelaia E; Olivé Marqué A; Sangüesa Gómez C; Freire González M; Aurrecoechea Aguinaga E; Raya Álvarez E; Tomero Muriel E; Montilla Morales C; Galindo Izquierdo M; Calvo-Alén J; Menor-Almagro R; Serrano Benavente B; Martinez-Barrio J; Hernández-Beriain JA; Ibañez Barceló M; Bonilla Hernan G; Rosas J; Salgado Pérez E; Fernández-Nebro A; Rua-Figueroa I
    Rheumatol Int; 2024 Nov; 44(11):2445-2455. PubMed ID: 39180523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Characteristics and Risk Factors of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis Based on Observational Studies.
    Xu T; Zhang G; Lin H; Xie Y; Feng Y; Zhang X; Dong G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):295-303. PubMed ID: 31440948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endotoxin induces late increase in the production of pulmonary proinflammatory cytokines in murine lupus-like pristane-primed model [corrected].
    Chae BS; Park JS; Shin TY
    Arch Pharm Res; 2006 Apr; 29(4):302-9. PubMed ID: 16681036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.
    Satoh M; Kumar A; Kanwar YS; Reeves WH
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10934-8. PubMed ID: 7479913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downregulation of hippocampal NR2A/2B subunits related to cognitive impairment in a pristane-induced lupus BALB/c mice.
    Luciano-Jaramillo J; Sandoval-García F; Vázquez-Del Mercado M; Gutiérrez-Mercado YK; Navarro-Hernández RE; Martínez-García EA; Pizano-Martínez O; Corona-Meraz FI; Bañuelos-Pineda J; Floresvillar-Mosqueda JF; Martín-Márquez BT
    PLoS One; 2019; 14(9):e0217190. PubMed ID: 31498792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pristane cadmium chloride nanoemulsion accelerates the onset of systemic lupus erythematosus in a C57BL/6 mouse model.
    Jin YB; Qian SH; Xiang ST; Zhang JJ; Zhang MG; Ding XH
    Lupus; 2023 Apr; 32(4):500-507. PubMed ID: 36748829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients.
    Wang CR; Liu MF; Weng CT; Lin WC; Li WT; Tsai HW
    Scand J Rheumatol; 2018 Sep; 47(5):392-399. PubMed ID: 29916287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
    Yamaguchi T; Kakefuda R; Tajima N; Sowa Y; Sakai T
    Int J Oncol; 2011 Jul; 39(1):23-31. PubMed ID: 21523318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus.
    Tse JR; Schwab KE; McMahon M; Simon W
    Lupus; 2015 Jun; 24(7):756-9. PubMed ID: 25527066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.